ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,164.12
-0.19%
Dow Jones
39,118.86
-0.12%
Gold vs US Dollar
2,326.73
0.00%
Brent Oil
84.85
0.00%
Bitcoin
61,012.14
1.16%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vir Biotechnology Inc (VIR)

  7. Vir Biotechnology Inc (VIR) News

Vir Biotechnology (VIR)

Vir Biotechnology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIR
DateTimeSourceHeadlineSymbolCompany
26/06/202413:05Business WireVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionNASDAQ:VIRVir Biotechnology Inc
12/06/202421:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
05/06/202411:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
05/06/202410:30Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentNASDAQ:VIRVir Biotechnology Inc
03/06/202417:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
03/06/202416:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
31/05/202419:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
31/05/202419:42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
29/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
29/05/202421:05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
29/05/202413:05Business WireVir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
23/05/202421:05Business WireVir Biotechnology to Host 2024 Annual Meeting of StockholdersNASDAQ:VIRVir Biotechnology Inc
22/05/202413:05Business WireMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024NASDAQ:VIRVir Biotechnology Inc
21/05/202413:17Business WireVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024NASDAQ:VIRVir Biotechnology Inc
14/05/202421:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRVir Biotechnology Inc
02/05/202421:05Business WireVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
30/04/202421:05Business WireVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024NASDAQ:VIRVir Biotechnology Inc
18/04/202413:00Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsNASDAQ:VIRVir Biotechnology Inc
11/04/202421:30Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:VIRVir Biotechnology Inc
05/03/202413:05Business WireVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleNASDAQ:VIRVir Biotechnology Inc
27/02/202400:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
27/02/202400:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
27/02/202400:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
27/02/202400:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
26/02/202421:27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
26/02/202421:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRVir Biotechnology Inc
23/02/202413:05Business WireVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:VIRVir Biotechnology Inc
22/02/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
22/02/202421:05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
20/02/202421:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:VIR

Your Recent History

BIT
F3Q3VS
Vontobel
LSE
FJ77
Bk. America 28
NYSE
GDF
NYSE
PNN.A
Penn Engineering
BIT
F14229
Vontobel Financial Produ...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved